Potassium ion-competitive acid blockers include volnoxan. Potassium ion-competitive acid blockers reversibly inhibit H+-K+-ATPase activity in a potassium ion-competitive manner, inhibit the production of gastric acid by staying in the cellular parts of the gastric wall for a long time, and effectively inhibit the formation of mucosal damage in the upper part of the gastrointestinal tract. The efficacy of Vonorasan is mainly to inhibit the secretion of gastric acid for reflux esophagitis. Common side effects include immune impairment, hepatic impairment and allergic reactions. The overall physiological functions (e.g. liver and kidney functions) of elderly patients are decreased, therefore, vonorasan should be used with caution in elderly patients. Vonorasan should be avoided during breastfeeding, and when the drug must be administered, breastfeeding should be stopped first. The drug needs to be used under medical supervision, and should not be taken blindly on its own, as this may lead to adverse reactions.